Compare C & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | C | JNJ |
|---|---|---|
| Founded | 1812 | 1886 |
| Country | United States | United States |
| Employees | 226000 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.2B | 542.4B |
| IPO Year | N/A | 2003 |
| Metric | C | JNJ |
|---|---|---|
| Price | $134.65 | $236.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | $134.94 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 7.5M | 6.2M |
| Earning Date | 04-14-2026 | 04-14-2026 |
| Dividend Yield | 1.88% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $24.26 | $6.63 |
| Revenue Next Year | $3.63 | $7.43 |
| P/E Ratio | ★ $16.63 | $108.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.11 | $149.04 |
| 52 Week High | $135.83 | $251.71 |
| Indicator | C | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 61.48 |
| Support Level | $94.96 | $233.83 |
| Resistance Level | N/A | $246.40 |
| Average True Range (ATR) | 3.45 | 4.20 |
| MACD | 0.84 | 0.96 |
| Stochastic Oscillator | 90.34 | 93.60 |
Citigroup is a global financial powerhouse that orchestrates the movement of $5 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm remains a leader on the global stage, servicing 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, steps have been taken to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.